NO148925C - Analogifremgangsmaate til fremstilling av 5-metyl-isoksazol-4-karboksylsyre-(4-trifluormetyl)-anilid med antiflogistisk og antireumatisk virkning - Google Patents

Analogifremgangsmaate til fremstilling av 5-metyl-isoksazol-4-karboksylsyre-(4-trifluormetyl)-anilid med antiflogistisk og antireumatisk virkning

Info

Publication number
NO148925C
NO148925C NO794094A NO794094A NO148925C NO 148925 C NO148925 C NO 148925C NO 794094 A NO794094 A NO 794094A NO 794094 A NO794094 A NO 794094A NO 148925 C NO148925 C NO 148925C
Authority
NO
Norway
Prior art keywords
rumatic
isoxsazol
antiflogistic
trifluormethyl
anilide
Prior art date
Application number
NO794094A
Other languages
English (en)
Norwegian (no)
Other versions
NO794094L (no
NO148925B (no
Inventor
Friedrich-Johannes Kaemmerer
Rudolf Schleverbach
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of NO794094L publication Critical patent/NO794094L/no
Publication of NO148925B publication Critical patent/NO148925B/no
Publication of NO148925C publication Critical patent/NO148925C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
NO794094A 1978-12-16 1979-12-14 Analogifremgangsmaate til fremstilling av 5-metyl-isoksazol-4-karboksylsyre-(4-trifluormetyl)-anilid med antiflogistisk og antireumatisk virkning NO148925C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19782854439 DE2854439A1 (de) 1978-12-16 1978-12-16 Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung

Publications (3)

Publication Number Publication Date
NO794094L NO794094L (no) 1980-06-17
NO148925B NO148925B (no) 1983-10-03
NO148925C true NO148925C (no) 1984-01-11

Family

ID=6057414

Family Applications (1)

Application Number Title Priority Date Filing Date
NO794094A NO148925C (no) 1978-12-16 1979-12-14 Analogifremgangsmaate til fremstilling av 5-metyl-isoksazol-4-karboksylsyre-(4-trifluormetyl)-anilid med antiflogistisk og antireumatisk virkning

Country Status (25)

Country Link
US (2) US4284786A (da)
EP (1) EP0013376B1 (da)
JP (1) JPS5583767A (da)
AR (2) AR222680A1 (da)
AT (1) ATE1067T1 (da)
AU (1) AU529341B2 (da)
BG (1) BG60764B2 (da)
CA (1) CA1129867A (da)
DE (2) DE2854439A1 (da)
DK (1) DK149886C (da)
EG (1) EG13926A (da)
ES (2) ES486750A1 (da)
FI (1) FI64154C (da)
GR (1) GR72731B (da)
HU (1) HU178015B (da)
IE (1) IE49126B1 (da)
IL (1) IL58951A (da)
LU (1) LU90466I2 (da)
MX (2) MX6174E (da)
NL (1) NL990037I2 (da)
NO (1) NO148925C (da)
NZ (1) NZ192400A (da)
PH (1) PH16627A (da)
PT (1) PT70596A (da)
ZA (1) ZA796793B (da)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3247454A1 (de) * 1982-12-22 1984-06-28 Laboratorios Bago S.A., Buenos Aires Substituierte 3-phenyl-5-methyl-isoxazol-4-carboxy-anilide, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
FR2538806B1 (fr) * 1982-12-30 1986-02-21 Bago Sa Labor Composes phenyl-3 methyl isoxazole-5 carboxy-4 anilides substitues, actifs therapeutiquement contre l'inflammation et la douleur
US5268382A (en) * 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
DE3534440A1 (de) * 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
US4935434A (en) * 1988-01-26 1990-06-19 Bristol-Myers Company Antiarthritic isoxazole-4-carboxamides
FR2662692B1 (fr) * 1990-05-30 1995-04-28 Novapharme Derives heterocycliques doues d'activite anticonvulsivante, procede de preparation et composition pharmaceutique.
US5258397A (en) * 1988-11-30 1993-11-02 Novapharme 3-Isoxazoyl derivatives endowed with anticonvulsant activity, procedure for their preparation and their pharmaceutical compositions
US5583150A (en) * 1989-08-18 1996-12-10 Alcon Laboratories, Inc. 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic anilides for the treatment of ocular diseases
DD297328A5 (de) * 1989-08-18 1992-01-09 �������@���������k���Kk�� 5-methyl-isoxalol-4-carbonsaeureanilide und 2 hydroxyethyliden-cyanoessigsaeureanilide zur behandlung von augenerkrankungen
US5001124A (en) * 1990-02-02 1991-03-19 Syntex (U.S.A.) Inc. 4-isoxazolecarboxamide derivatives
US5108999A (en) * 1990-02-02 1992-04-28 Syntex (U.S.A.) Inc. 4-isoxazolecarboxamide derivatives
EP0527736B1 (de) * 1990-05-18 1997-04-16 Hoechst Aktiengesellschaft Isoxazol-4-carbonsäureamide und hydroxyalkyliden-cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung
DE4127737A1 (de) * 1991-08-22 1993-02-25 Hoechst Ag Arzneimittel zur behandlung von abstossungsreaktionen bei organverpflanzungen
US6133301A (en) * 1991-08-22 2000-10-17 Aventis Pharma Deutschland Gmbh Pharmaceuticals for the treatment of rejection reactions in organ transplantations
DK0607776T3 (da) * 1993-01-08 1999-08-16 Hoechst Ag Anvendelse af leflunomid til inhibering af tumornekrosefaktor alfa
ES2125356T3 (es) * 1993-01-08 1999-03-01 Hoechst Ag Empleo de leflunomida para la inhibicion de interleuquina 8.
ATE174217T1 (de) * 1993-01-08 1998-12-15 Hoechst Ag Verwendung von leflunomid zur hemmung von interleukin 1 alpha
ATE174218T1 (de) * 1993-01-08 1998-12-15 Hoechst Ag Verwendung von leflunomid zur hemmung von interleukin 1 beta
TW314467B (da) * 1993-03-31 1997-09-01 Hoechst Ag
DE4323636A1 (de) * 1993-07-15 1995-01-19 Hoechst Ag Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
LT3589B (en) 1993-11-30 1995-12-27 Hoechst Ag Using of known combination for treatment of rejection reaction by transplantation of organs
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
US6335356B1 (en) 1994-01-07 2002-01-01 Sugen, Inc. Method of treating a patient by parenteral administration of a lipophilic compound
US5519042A (en) * 1994-01-13 1996-05-21 Hoechst Aktiengesellschaft Method of treating hyperproliferative vascular disease
US5624946A (en) * 1994-07-05 1997-04-29 Williams; James Use of leflunomide to control and reverse chronic allograft rejection
DK0787491T3 (da) * 1994-10-17 2000-10-16 Aventis Pharma Ltd Middel til forebyggelse og behandling af allergiske sygdomme af type I
US5721277A (en) * 1995-04-21 1998-02-24 Sugen, Inc. Compounds and methods for inhibiting hyper-proliferative cell growth
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
DE19539638A1 (de) * 1995-10-25 1997-04-30 Hoechst Ag Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen
DE19702988A1 (de) * 1997-01-28 1998-07-30 Hoechst Ag Isoxazol- und Crotonsäureamidderivate und deren Verwendung als Arzneimittel und Diagnostika
US6316479B1 (en) 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
EP0987256B1 (de) 1997-08-08 2001-10-17 Aventis Pharma Deutschland GmbH Kristallform von N-(4-Trifluormethylphenyl)-5-methylisoxazol-4-carbonsäureamid
US7691890B2 (en) 1998-03-11 2010-04-06 James W. Williams Anti-viral uses of leflunomide products
US20050255071A1 (en) * 1998-12-10 2005-11-17 Aventis Pharma Deutschland Gmbh Preparation having improved therapeutic breadth comprising nucleotide synthesis inhibitors
DE19908527C2 (de) * 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
US6566395B1 (en) 1999-05-25 2003-05-20 Biomedicines, Inc. Methods of treating proliferative disorders
DE19960443C2 (de) * 1999-12-15 2002-05-08 Aventis Pharma Gmbh Verfahren zur Auffindung von Nukleotidsyntheseinhibitoren mit weniger Nebenwirkungen
CA2397601A1 (en) * 1999-12-16 2001-06-21 Teva Pharmaceutical Industries, Ltd. Novel processes for making- and a new crystalline form of- leflunomide
SK12992002A3 (sk) * 2000-02-15 2003-05-02 Teva Pharmaceutical Industries Ltd. Spôsob syntézy leflunomidu
EP1473035A1 (en) * 2000-02-15 2004-11-03 Teva Pharmaceutical Industries Ltd. Leflunomide of high purity
AU2001284891A1 (en) * 2000-08-14 2002-02-25 Teva Pharmaceutical Industries Ltd. Micronized leflunomide
GB0123571D0 (en) 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
EP1935416A3 (en) 2001-04-05 2008-10-22 Aventis Pharma Inc (Z) -2-cyano-3-hydroxybut-2-enoic acid (4'-trifluoromethylphenyl) amide for the treatment of multiple sclerosis
WO2003042193A1 (en) * 2001-11-09 2003-05-22 Geneva Pharmaceuticals, Inc. Process for preparing 5-methylisoxazole-4-carboxylic-(4'-trifluoromethyl)-anilide
US20050158371A1 (en) * 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
US20060024376A1 (en) * 2004-07-30 2006-02-02 The University Of Chicago Methods and compositions for reducing toxicity associated with leflunomide treatment
US20090281106A1 (en) * 2005-08-31 2009-11-12 Kowa Co., Ltd Prophylactic and/or therapeutic method for rheumatoid arthritis
US9073997B2 (en) * 2007-02-02 2015-07-07 Vegenics Pty Limited Growth factor antagonists for organ transplant alloimmunity and arteriosclerosis
CN101817797B (zh) * 2009-02-26 2013-04-10 江苏亚邦爱普森药业有限公司 高纯度3-甲基-n-[4-(三氟甲基)苯基]-4-异噁唑甲酰胺的合成方法
US9138309B2 (en) 2010-02-05 2015-09-22 Allergan, Inc. Porous materials, methods of making and uses
US9205577B2 (en) * 2010-02-05 2015-12-08 Allergan, Inc. Porogen compositions, methods of making and uses
US11202853B2 (en) * 2010-05-11 2021-12-21 Allergan, Inc. Porogen compositions, methods of making and uses
JOP20190207A1 (ar) 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود
AU2019242628A1 (en) 2018-03-26 2020-09-24 Clear Creek Bio, Inc. Compositions and methods for inhibiting dihydroorotate dehydrogenase
US20230123588A1 (en) 2020-03-06 2023-04-20 Actelion Pharmaceuticals Ltd Methods of slowing brain volume loss
CA3221343A1 (en) 2021-10-11 2023-04-20 Allitia DIBERNARDO Methods of treating multiple sclerosis
CA3220702A1 (en) 2022-02-11 2023-08-17 Actelion Pharmaceuticals Ltd Methods of slowing an increase in brain ventricular volume

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087534A (en) * 1974-05-22 1978-05-02 David Ovadia N-haloalkylmio urazole pesticides
DE2524959C2 (de) * 1975-06-05 1983-02-10 Hoechst Ag, 6000 Frankfurt 5-Methyl-isoxazol-4-carbonsäureanilide, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Mittel
ES448386A1 (es) * 1975-06-05 1978-04-16 Hoechst Ag Procedimiento para la preparacion de anilidas de acido 5-me-til-isoxazol-4-carboxilico.
DE2654797A1 (de) * 1976-12-03 1978-06-08 Hoechst Ag Verfahren zur herstellung von isoxazolderivaten

Also Published As

Publication number Publication date
ES486758A1 (es) 1980-05-16
IL58951A (en) 1984-01-31
IE49126B1 (en) 1985-08-07
IL58951A0 (en) 1980-03-31
ZA796793B (en) 1980-11-26
US4351841A (en) 1982-09-28
PT70596A (de) 1980-01-01
DE2854439A1 (de) 1980-07-03
EP0013376A2 (de) 1980-07-23
AR226894A1 (es) 1982-08-31
LU90466I2 (fr) 2000-01-03
MX6174E (es) 1984-12-04
DK534279A (da) 1980-06-17
AR222680A1 (es) 1981-06-15
AU529341B2 (en) 1983-06-02
HU178015B (en) 1982-02-28
NZ192400A (en) 1982-02-23
BG60764B2 (bg) 1996-02-29
EP0013376A3 (en) 1980-09-17
DE2962929D1 (en) 1982-07-08
AU5385379A (en) 1980-06-19
JPH0133470B2 (da) 1989-07-13
NO794094L (no) 1980-06-17
NL990037I1 (nl) 2000-01-03
MX8403A (es) 1994-03-31
DK149886B (da) 1986-10-20
NL990037I2 (nl) 2000-01-03
FI793899A (fi) 1980-06-17
PH16627A (en) 1983-12-05
GR72731B (da) 1983-12-01
FI64154B (fi) 1983-06-30
US4284786A (en) 1981-08-18
EG13926A (en) 1982-09-30
NO148925B (no) 1983-10-03
DK149886C (da) 1987-04-21
IE792426L (en) 1980-06-16
EP0013376B1 (de) 1982-05-19
JPS5583767A (en) 1980-06-24
CA1129867A (en) 1982-08-17
ATE1067T1 (de) 1982-06-15
FI64154C (fi) 1983-10-10
ES486750A1 (es) 1980-06-16

Similar Documents

Publication Publication Date Title
NO148925C (no) Analogifremgangsmaate til fremstilling av 5-metyl-isoksazol-4-karboksylsyre-(4-trifluormetyl)-anilid med antiflogistisk og antireumatisk virkning
NO148100C (no) Fremgangsmaate og anordning for fremstilling av leggproteser
NO784324L (no) Fremgangsmaate for fremstilling av polymerisater av akrylsyre og/eller metakrylsyre
IT7969499A0 (it) Procedimento e dispositivo per la fabbricazione di cerniere lampo
DK320779A (da) Stivelsesholdigt naeringsmiddel fremgangsmaade til fremstilling af samme og fortykkelses iddel hertil
NO150879C (no) Fremgangsmaate for fremstilling av d-camforat av l-carnitinamid og d-camforat av d-carnitinamid
DK154879A (da) Fremgangsmaade til frembringelse af mikrobiologiske celler og anvendelse heraf til frembringelse af oxidationsproukter
NO794181L (no) Fremgangsmaate for fremstilling av merkaptoacetyl-prolin- og pipekolsyre-derivater
DK185079A (da) Azolopyrimidinoner og fremgangsmaade til fremstilling deraf
DK132779A (da) Fremgangsmaade til fremstilling af cishexahydrodibenzoepyranoner og tetrahydrobenzoxoiner
NO821595L (no) Fremgangsmaate for fremstilling av 2-(2-benzyl-3-merkapto-propionylamino)-derivater av 1-alkanoler og av 4-metyltiosmoersyre
NO148802C (no) Fremgangsmaate og belegningspreparat for fremstilling av biologisk aktive preparater med regulert frigjoerelse av aktive bestanddeler
NO801046L (no) Penem-3-karboksylsyrederivater og fremgangsmaate til fremstilling av samme
NO781501L (no) Fremgangsmaate og form for fremstilling av flere paa hverandre foelgende bygge-elementer
DK379380A (da) Fremgangsmaade til fremstilling af 1-aminocyclopropan-carbolsyre og derivater deraf
DK496977A (da) Fremgangsmaade til fremstilling af 0-alkylerede hydroxylaminer og syreadditionssalte deraf
NO790765L (no) Fremgangsmaate til fremstilling av urinstoffer og amidoforbindelser
DK359577A (da) Fremgangsmade til fremstilling af 2-phenylaminoimidazolin-(2) og syreadditionssalte
DK121776A (da) Fremgangsmade til fremstilling af tricosen-(9) og heneicosen-(9)
DK157136C (da) Fremgangsmaade til fremstilling af 6-beta-iodpenicillansyre og estre heraf
DK490076A (da) Fremgangsmade til fremstilling af 3-aminomethylen-6,7-dimethoxy-2-methyl-oxo1,2,3,4-tetrahydro-1-quinolin-carboxylsyre-estere og mellemprodukter herved
NO802277L (no) Fremgangsmaate til fremstilling av terapeutisk aktive 25-halocholest-5-en-3beta,22-dioler og estere derav
DK209879A (da) Fremgangsmaade til fremstilling af aryleddikesyrederivater nellemprodukter hertil og disses fremstilling
NO782707L (no) Fremgangsmaate for fremstilling av nye 2-pyridyl- og 2-pyrimidylaminobenzoesyrer
NO146278C (no) Fremgangsmaate til fremstilling av kvadratsyre